Why Farbe Firma is the Top Manufacturer of Phytomenadione (Vitamin K1) Injection
- Maulik Sudani
- May 27
- 7 min read
Last Updated: May 27, 2026
TL;DR: Phytomenadione (Vitamin K1) Injection — a sterile, ready-to-use parenteral suspension or mixed-micelle solution of phytomenadione, supplied most commonly as 10 mg/mL in 1 mL ampoules (10 mg) and 2 mg/0.2 mL paediatric ampoules — is the standard treatment and prophylaxis for vitamin-K-deficiency bleeding in newborns, the reversal of warfarin and other vitamin-K-antagonist anticoagulation, and the management of haemorrhage in obstructive jaundice, malabsorption and severe liver disease. It restores hepatic synthesis of clotting factors II, VII, IX and X within hours of administration. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Phytomenadione (Vitamin K1) Injection at our Gujarat, India facility and supplies it to hospital tenders, neonatal and obstetric programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Fat-soluble vitamin / antihaemorrhagic — Phytomenadione (Vitamin K1) Injection supplies the cofactor required by hepatic γ-glutamyl carboxylase to activate clotting factors II, VII, IX and X plus proteins C and S. It is the WHO Essential Medicine for neonatal vitamin-K-deficiency-bleeding prophylaxis at birth, for warfarin and superwarfarin reversal, and for haemorrhage in cholestasis, malabsorption and severe liver disease. The parenteral route is preferred when oral absorption is impaired or speed is critical.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule filling lines, dedicated light-protected handling for the photosensitive phytomenadione molecule, validated mixed-micelle or emulsion technology, and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets including neonatal vitamin-K-prophylaxis tenders for ministry-of-health programmes.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready amber-glass packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Phytomenadione (Vitamin K1) Injection Demands a Premium Manufacturer
Phytomenadione (Vitamin K1) Injection is one of the quietest but most essential drugs in obstetric, neonatal and emergency medicine. Every newborn in a modern delivery suite receives a single intramuscular dose at birth to prevent vitamin-K-deficiency bleeding, the historic cause of catastrophic neonatal intracranial haemorrhage that public-health programmes have all but eliminated through this one intervention. Every patient who arrives in emergency with a major bleed on warfarin, or who has accidentally ingested a long-acting rodenticide, needs intravenous or slow-intravenous phytomenadione alongside prothrombin-complex concentrate to restore clotting. Every cholestatic, malabsorptive or severely hepatic patient with a prolonged INR depends on parenteral Vitamin K1 because the oral route cannot be trusted. Because the drug is given to a tiny newborn or to an actively bleeding adult, the consequences of a sub-potent, contaminated or precipitated ampoule are immediate and irreversible.
That clinical context places real demands on the manufacturer. Phytomenadione is a highly lipophilic, photosensitive vitamin that has to be formulated as a mixed-micelle or polyoxyethylated-castor-oil-based solution or as a fine emulsion to achieve a clear, injectable parenteral. The solution must be protected from light through its entire shelf life, must be crystal clear, free of visible and sub-visible particulate, reliably sterile and endotoxin-free, and stable across the long, hot supply chains of the emerging-market hospital systems where Farbe Firma's customers operate. Slow intravenous administration is critical to avoid the rare but well-documented anaphylactoid reaction described with this molecule, and the ampoule design and labelling must support that clinical reality. Choosing a Phytomenadione (Vitamin K1) Injection manufacturer that treats photostability, micellar formulation precision and validated stability as core engineering disciplines is what keeps neonatal and emergency wards safe.
What Sets a World-Class Phytomenadione (Vitamin K1) Injection Manufacturer Apart
A world-class manufacturer of Phytomenadione (Vitamin K1) Injection invests in three areas that weaker suppliers underfund: photostable mixed-micelle or emulsion formulation, precision assay control of a lipophilic vitamin, and a sterility and particulate programme built for a small-volume parenteral that meets a newborn baby. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade phytomenadione sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The mixed-micelle or emulsion system is built around validated solubilisers (polyoxyethylated castor oil, lecithin/glycocholate or equivalent), the solution pH is tightly controlled, in-process assay confirms label strength, and filling is performed under ISO Class 5 air in amber glass ampoules with light-protective secondary packaging to shield against UV-driven degradation. Container-closure integrity is verified, and stability is tracked under ICH Q1A long-term and accelerated conditions as well as ICH Q1B photostability protocols. World-class plants also keep paediatric strengths to a rigorous fill-volume specification, because in neonatal use the difference between 0.2 mL and 0.5 mL of a 10 mg/mL solution is the difference between a prophylactic dose and an overdose.
Quality Systems Behind Every Phytomenadione (Vitamin K1) Injection
Every Farbe Firma Phytomenadione (Vitamin K1) Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substance and degradation-product profiling, cis/trans isomer ratio control, pH, particle-size distribution where the formulation is a fine emulsion, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification appropriate to the adult and paediatric ampoule formats. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Phytomenadione (Vitamin K1) Injection they buy today will still meet specification when it reaches the newborn or the bleeding adult months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Phytomenadione (Vitamin K1) Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across critical-care, obstetric, neonatal, anti-infective and supportive-care categories. For Phytomenadione (Vitamin K1) Injection specifically, we supply 10 mg/mL in 1 mL amber-glass ampoules (10 mg adult strength) and 2 mg/0.2 mL paediatric ampoules in mixed-micelle or polyoxyethylated-castor-oil-based formulations, with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Phytomenadione (Vitamin K1) Injection at tender scale — and ministry-of-health neonatal-vitamin-K-prophylaxis procurements are almost always high-volume, paediatric and labelling-sensitive — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, mixed-micelle formulation, photostability strategy, particulate control, sterilisation, container-closure and stability choices in real detail. For a drug given to a newborn baby on its first day of life, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Phytomenadione (Vitamin K1) Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Phytomenadione (Vitamin K1) Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified amber-ampoule filling lines, dedicated light-protected handling, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Phytomenadione (Vitamin K1) Injection do you supply?
Our standard presentations are 10 mg/mL in 1 mL amber-glass ampoules (10 mg adult strength) and 2 mg/0.2 mL paediatric ampoules for neonatal vitamin-K prophylaxis. Mixed-micelle and polyoxyethylated-castor-oil-based formulations, custom fill volumes, vial presentations and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Phytomenadione (Vitamin K1) Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia, including neonatal-vitamin-K-prophylaxis tender programmes for ministry-of-health buyers.
How does Farbe Firma assure the potency and photostability of Phytomenadione (Vitamin K1) Injection?
We control the mixed-micelle or emulsion system to a validated specification, run HPLC assay and related-substances and cis/trans isomer testing on every batch, package in amber glass with light-protective secondary cartons, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability. Endotoxin, sterility and container-closure integrity are confirmed on every batch.
What is the minimum order quantity for Phytomenadione (Vitamin K1) Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For both adult 10 mg and paediatric 2 mg presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments